FRA: MVR0

Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for its fostroxacitabine bralpamide (fostrox) and its use in the treatment of liver cancer. The patent, which remains valid until 2035 with potential for extensions, is a significant milestone for Medivir, considering China’s large population of…